Quick Answer
NEKTAR THERAPEUTICS reported Operating Income Loss of -$140.10 million for the year ending 2025.
- NEKTAR THERAPEUTICS showed a decrease of -33.2% in Operating Income Loss from 2024 to 2025.
- This data is from NEKTAR THERAPEUTICS's annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2014: -$22.92 million | Q3 2014: $80.32 million | Q4 2014: -$37.49 million | Q1 2015: $43.04 million | Q2 2015: -$43.47 million | Q3 2015: $419.0 thousand | Q4 2015: -$29.36 million | Q1 2016: -$9.48 million | Q2 2016: -$38.33 million | Q3 2016: -$32.90 million | Q4 2016: -$32.15 million | Q1 2017: -$54.44 million | Q2 2017: -$50.66 million | Q3 2017: $69.49 million | Q4 2017: -$24.03 million | Q1 2018: -$86.74 million | Q2 2018: $973.60 million | Q3 2018: -$98.63 million | Q4 2018: -$100.30 million | Q1 2019: -$120.69 million | Q2 2019: -$110.97 million | Q3 2019: -$98.74 million | Q4 2019: -$109.64 million | Q1 2020: -$133.63 million | Q2 2020: -$77.71 million | Q3 2020: -$103.05 million | Q4 2020: -$110.72 million | Q1 2021: -$109.39 million | Q2 2021: -$110.21 million | Q3 2021: -$113.60 million | Q4 2021: -$112.91 million | Q1 2022: -$116.56 million | Q2 2022: -$152.84 million | Q3 2022: -$54.30 million | Q1 2023: -$134.71 million | Q2 2023: -$50.60 million | Q3 2023: -$44.86 million | Q1 2024: -$35.43 million | Q2 2024: -$49.77 million | Q3 2024: -$34.35 million | Q1 2025: -$44.54 million | Q2 2025: -$36.23 million | Q3 2025: -$31.67 million.
- Over the full 17 years of available data (2009 to 2025), NEKTAR THERAPEUTICS's Operating Income Loss has declined by 47.3%.
- Historical annual values: Fiscal year 2025: -$140.10 million | Fiscal year 2024: -$105.20 million | Fiscal year 2023: -$263.68 million | Fiscal year 2022: -$376.17 million | Fiscal year 2021: -$446.10 million | Fiscal year 2020: -$425.11 million | Fiscal year 2019: -$440.04 million | Fiscal year 2018: $687.93 million | Fiscal year 2017: -$59.64 million | Fiscal year 2016: -$112.86 million | Fiscal year 2015: -$29.37 million | Fiscal year 2014: -$16.49 million | Fiscal year 2013: -$120.13 million | Fiscal year 2012: -$141.20 million | Fiscal year 2011: -$123.94 million | Fiscal year 2010: -$28.26 million | Fiscal year 2009: -$95.13 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: